Cancer genomics firm Tempus' pact with Cleveland's UH Seidman Cancer Center adds to its list of partnerships with academic oncology centers.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
The company had encouraging results for its breast cancer tests and provided an update on the development of its bladder cancer test.
Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.
The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.
The researchers found preliminary evidence that some inherited cancer mutations may be more or less common in African-American women than Caucasian women.
A team of German researchers reported that loss-of-function mutations in FANCM were more common among cases that developed the disease at a young age.
Researchers analyzed the exomes of metastatic tumor samples from patients who died of breast cancer to piece together the genomic evolution.
Investigators will compare results using Biocept's platform in cerebrospinal fluid to current standard methods for diagnosing leptomeningeal metastases.
The firm's vaccine, which previously led to tumor regression in a patient with metastatic breast cancer, is scheduled to enter clinical trials in 2017.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.